Investor relations & Media

  1. Home
  2. Investor relations & Media
Developing best-in-class therapies that have the potential to offer life-changing benefits for people with cancer and autoimmune diseases

Autolus is building a fully-integrated, next generation CAR T company. It is committed to the development and commercialization of obe-cel in r/r Adult ALL and is progressing opportunities for obe-cel in additional indications alongside its preclinical and clinical pipeline for hematological malignancies and solid tumors.

Quick links

Corporate Presentation for Investors

Developing and Delivering a New Generation of T Cell Therapies

Download Autolus Corporate Presentation pdf (2.00Mb)

Events

Our team regularly attends key industry conferences to meet with investors and potential partners. Our scientists also represent Autolus at key scientific and medical congresses.

Find out more

Corporate governance

The Board of Directors of Autolus Therapeutics plc sets high standards for our employees, officers and directors. Implicit in this philosophy is the importance of sound corporate governance.

Find out more

Sign up for updates

Register to receive email alerts from Autolus.

Email alerts
News & Media
Events